Apeloa Pharmaceutical (000739.SZ) has obtained a drug registration certificate and a notice of approval for the listing application of chemical raw materials.

Apeloa Pharmaceutical (000739.SZ) announced that its subsidiary Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd. has recently received the Drug Registration Certificate for ephedrine sulfate injection issued by the National Medical Products Administration, as well as the Approval Notice for the listing application of ephedrine sulfate as a chemical raw material. The company's ephedrine sulfate injection is the first in China to receive approval for listing, equivalent to passing the generic drug consistency evaluation. This drug is used to treat clinically significant hypotension that occurs under anesthesia. The approval for listing of ephedrine sulfate as a chemical raw material and the issuance of the drug registration certificate for ephedrine sulfate injection demonstrate the company's synergistic strategy of integrating raw materials and formulations, which will help enhance the market competitiveness of the product, enrich the company's product pipeline, and have a positive impact on the company's business development.